Sequana Medical has a clear focus on innovative treatments for diuretic-resistant fluid overload. Excess fluid in the body is a major problem in many large diseases. Discover more in our annual report here: sequanamedical.com/wp-content/upl… #sequanamedical #AnnualReport #transforminglives

#Proud that the abstract on the results of our RED DESERT study has been selected for presentation at world's leading #HeartFailure congress, as part of the Late Breaking Science Results! Click here to register for the event: lnkd.in/dFNpeTN #HeartFailure2021

Sequana Medical NV's proprietary alfapump and Direct Sodium Removal (DSR) platforms are being advanced as long-term treatments for diuretic-resistant fluid overload related to liver disease, malignant ascites and heart failure (HF). $SEQUA #research #healthcare hubs.ly/H0QG_yK0

Curious to learn more about #fluidoverload and our #alfapump and #DSR technologies, then watch this video from our CEO Ian Crosbie pitching Sequana Medical at De Belegger on Tour #DBOT: youtube.com/watch?v=rFt7WC… #sequanamedical #transforminglives

Watch this animated video and learn more about the impact of heart failure and diuretic-resistant fluid overload on patients and healthcare systems: youtu.be/1sdydwaJSoU #worldheartday #sequanamedical #heartfailure #fluidoverload #diureticresistance #transforminglives

Op zaterdag 23 oktober nemen wij deel aan de VFB Happening in Kinepolis Antwerpen. Graag verwelkomen Kirsten Van Bockstaele en Lies Vanneste jullie op stand 2018. #VFB #sequanamedical #event #welkom

We are proud to announce that we now have a globally certified #QMS in place, which is an important element of the package required for #alfapump approval in the US and Canada. Read the full press release here: sequanamedical.com/press-releases…

Join us on Saturday 20 November for Finance Avenue at Tour & Taxis in Brussels. You can find us at booth #122 – hall 1. Our workshop is at 11:15 in Finance Corner 3. Hope to see you there! #finav21 #sequanamedical #transforminglives

Pleased to announce that all patients have been enrolled in our POSEIDON study - an important step in bringing the alfapump closer to market approval in the US and Canada. Read the full press release here: sequanamedical.com/press-releases… #sequanamedical #alfapump #transforminglives

Another important milestone: positive interim results from the SAHARA DESERT study, indicating, for the first time, the ability of repeated #DSR therapy to safely, effectively and rapidly eliminate persistent #congestion in decompensated HF lnkd.in/ecNf2saB #sequanamedical

Join us today for our webcast on the positive interim results from SAHARA DESERT, the #alfapump #DSR study in heart failure patients with persistent #congestion. Register here: lnkd.in/e_Z6vMeD #webinar #sequanamedical #heartfailure #diureticresistance #transforminglives

CEO, Ian Crosbie, together with other medtech executives, will be speaking at LifeSci Partners' virtual panel on "The Mindset for Medtech/Digital Tools in 2022", on January 5th at 8pm CET / 2pm ET. Click here for more info and to register: lnkd.in/dVhmAWxi #panel #MEDTECH

Tune in to Ep. 28 of the Benchtop Bios Podcast, featuring Ian Crosbie, CEO of Sequana Medical NV Medical who will discuss Sequana Medical’s novel approaches to drain fluid away when diuretics are no longer effective. Listen Here: lifesci.events/BBli

Proud to announce that our Annual Report 2021 has been published today. Check it out here: lnkd.in/gkqwnPwx #annualreport #sequanamedical #alfapump #DSR #transforminglives

Join us for our webcast on 8 September at 3pm CEST and get an update on the achievements and an outlook for the remainder of the year and beyond. Register for the webcast here: lnkd.in/e-axx4Vq #sequanamedical #alfapump #DSR #liverdisease #heartfailure #financialresults

Sequana Medical NV is pleased to announce its H1 2022 results and business update today! We have made important progress with both our #liverdisease and #heartfailure programs. Read the results here: sequanamedical.com/press-releases… #sequanamedical #alfapump #DSR #transforminglives

Ian Crosbie, CEO of @Sequanamed, will be at Jefferies London Healthcare, where he will provide an update on the #alfapump program and on #DSR, the disease-modifying drug program for the treatment of heart failure. If you would like to meet, get in touch! #JefferiesHealthcare

Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON cardiacvascularnews.com/sequana-medica…

📢 PRESS NEWS: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego. More info on: lnkd.in/eJPMjJSf #SequanaMedical #alfapump #POSEIDON #study #US #TheLiverMeeting

📢Press news: Sequana Medical announces the publication in Kidney Medicine highlighting the benefits of its proprietary DSR 2.0 in its Direct Sodium Removal program as a potential therapy for cardiorenal syndrome and diuretic resistance in heartfailure